What is ZYUS Life Sciences?
ZYUS Life Sciences, a Canadian entity, is dedicated to the global advancement and commercialization of novel cannabinoid-based therapeutics. The company's strategy involves rigorous clinical research and intellectual property development to produce high-quality cannabinoid products, including oils, softgels, and topical creams, for patient access worldwide. ZYUS aims to establish cannabinoids as a recognized standard of care and explore the therapeutic potential of protein-based formulations, seeking to profoundly impact patient well-being. The company's vision centers on elevating the science of well-being through its innovative approach.
How much funding has ZYUS Life Sciences raised?
ZYUS Life Sciences has raised a total of $73K across 1 funding round:
Private Equity
$73K
Private Equity (2025): $73K, investors not publicly disclosed
What's next for ZYUS Life Sciences?
With substantial expansion capital secured, ZYUS Life Sciences is poised for a significant growth phase. The company's focus on developing cannabinoid-based therapeutics and advancing the science of well-being suggests strategic investments in research and development, clinical trials, and potentially, market penetration initiatives. The Series B/C stage funding indicates a transition towards scaling operations and broadening the reach of its product candidates, aiming to solidify its position in the evolving life sciences landscape and achieve its vision of transforming patient care.
See full ZYUS Life Sciences company page
